Expression of concern
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Paper Information
Record ID:
43835
Author(s):
Journal:
Publication Date:
August 05, 2022
Retraction Date:
March 14, 2023
(2.7 years years ago)
Subjects:
Institutions:
- Department of Dermatology, Skin Cancer Center, University Hospital Zurich, Zurich, Switzerland
- IRCCS Istituto Europeo di Oncologia, Milan, Italy
- F Hoffman-La Roche, Basel, Switzerland
- Hospital de Clínicas de Porto Alegre, Unidade de Pesquisa Clinica em Oncologia, Porto Alegre, Brazil
- Gustave Roussy and Université Paris-Saclay, Villejuif-Paris, France
- Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy
- Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
- IRCCS Ospedale Policlinico San Martino, Genova, Italy
- Onkologikoa Hospital, Donostia, Spain
- Országos Onkológiai Intézet, Budapest, Hungary
- Hospital Universitario Virgen Macarena, Clinical Oncology Department and Medicine Department, University of Seville, Seville, Spain
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Article Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Expression of concern Details
Retraction Reasons:
Nature of Retraction:
Expression of concern
Retraction Notice:
10.1016/S1470-2045(23)00111-0Citations (40)
40
Total Citations30
Post-Retraction(75.0%)
9
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
2
Within 30 days
27
Within 1 year
0
After 2+ years
601
Days since retraction (latest)
Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview
Rupesh Kotecha, Alonso La Rosa, Paul D. Brown et al. (9 authors)
Neuro-Oncology
Open Access
Published: Nov 2024
4 citations
4 citations
601 days after retraction
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Rui Han, Xiwu Rao, Huiling Zhou et al. (4 authors)
International Journal of Nanomedicine
Open Access
Published: May 2024
9 citations
9 citations
414 days after retraction
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey
Marie Fabre, A. Lamoureux, Laurent Meunier et al. (9 authors)
Melanoma Research
Published: Mar 2024
1 citation
1 citation
380 days after retraction
Primary Cutaneous Melanoma—Management in 2024
Anthony Dixon, Michael J Sladden, Christos C. Zouboulis et al. (9 authors)
Journal of Clinical Medicine
Open Access
Published: Mar 2024
8 citations
8 citations
363 days after retraction
Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses
Livia Onofrio, Aurora Gaeta, Oriana D’Ecclesiis et al. (6 authors)
Applied Sciences
Open Access
Published: Mar 2024
1 citation
1 citation
359 days after retraction
Levothyroxine personalized treatment: is it still a dream?
Carlo Cappelli, Elisa Gatta, Salvatore Ippolito
Frontiers in Endocrinology
Open Access
Published: Jan 2024
3 citations
3 citations
300 days after retraction
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers
Khine Shan, Tauseef Ur Rehman, S. G. Ivanov et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Jan 2024
15 citations
15 citations
295 days after retraction
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Lisa H. Butterfield, Yana G. Najjar
Nature reviews. Immunology
Published: Dec 2023
130 citations
130 citations
267 days after retraction
Quoi de neuf en oncodermatologie ?
Philippe Saïag
Annales de Dermatologie et de Vénéréologie - FMC
Published: Dec 2023
262 days after retraction
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS
Katharina C. Kähler, Dirk Debus, Gaston Schley et al. (15 authors)
Melanoma Research
Open Access
Published: Nov 2023
2 citations
2 citations
244 days after retraction
DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway
Ke Mi, Lizhong Zeng, Yang Chen et al. (7 authors)
Cellular Signalling
Published: Nov 2023
6 citations
6 citations
235 days after retraction
Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers
Elena Brozos-Vázquez, Claudia Rodríguez-López, A. Cortegoso-Mosquera et al. (8 authors)
Frontiers in Immunology
Open Access
Published: Nov 2023
9 citations
9 citations
234 days after retraction
Management of melanoma central nervous system metastases
Piotr Rutkowski, Dorota Kiprian, Tomasz Świtaj et al. (9 authors)
Oncology in Clinical Practice
Open Access
Published: Oct 2023
227 days after retraction
Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
Kangjie Shen, Qiangcheng Wang, Lu Wang et al. (18 authors)
European journal of medical research
Open Access
Published: Sep 2023
11 citations
11 citations
186 days after retraction
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care
Inna Smalley, Adrienne Boire, Priscilla K. Brastianos et al. (11 authors)
Pigment Cell & Melanoma Research
Open Access
Published: Aug 2023
5 citations
5 citations
164 days after retraction
Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
Qi Cai, Xiaoqing Li, Hejian Xiong et al. (14 authors)
Nature Communications
Open Access
Published: Aug 2023
39 citations
39 citations
154 days after retraction
Current Treatment of Melanoma Brain Metastases
Agnieszka Nowacka, Anna Fajkiel-Madajczyk, Jakub Ohla et al. (11 authors)
Cancers
Open Access
Published: Aug 2023
9 citations
9 citations
153 days after retraction
The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Reinhard Dummer, Michèle Welti, Egle Ramelyte
Journal of Translational Medicine
Open Access
Published: Aug 2023
6 citations
6 citations
144 days after retraction
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin Zheng, Qin Zhou, Jianan Cheng et al. (5 authors)
Frontiers of Medicine
Published: Aug 2023
4 citations
4 citations
140 days after retraction
Macrophage’s role in solid tumors: two edges of a sword
Arian Jahandideh, Mahsa Yarizadeh, Maryam Noei-Khesht Masjedi et al. (13 authors)
Cancer Cell International
Open Access
Published: Jul 2023
24 citations
24 citations
139 days after retraction
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer
Lu Zhang, Zhi Li, Meng Zhang et al. (11 authors)
Medical Oncology
Published: Jul 2023
1 citation
1 citation
139 days after retraction
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies et al. (5 authors)
The Lancet
Published: Jul 2023
377 citations
377 citations
132 days after retraction
Retraction and republication—Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Unknown Authors
The Lancet Oncology
Open Access
Published: Jul 2023
1 citation
1 citation
122 days after retraction
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine
Open Access
Published: Jul 2023
18 citations
18 citations
121 days after retraction
What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?
Piotr Rutkowski, Paweł Rogala
Expert Opinion on Pharmacotherapy
Open Access
Published: May 2023
52 days after retraction
Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids
Simona Manacorda, Maria De Toro Carmena, Ciara Malone et al. (7 authors)
European Journal of Cancer
Published: Apr 2023
10 citations
10 citations
45 days after retraction
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
Andrea Boutros, Enrica T. Tanda, Elena Croce et al. (14 authors)
European Journal of Cancer
Published: Apr 2023
23 citations
23 citations
41 days after retraction
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Maximilian Haist, Henner Stege, Michael Kuske et al. (7 authors)
Cancer and Metastasis Reviews
Open Access
Published: Apr 2023
14 citations
14 citations
23 days after retraction
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Claudia Trojaniello, Francesca Sparano, Eleonora Cioli et al. (4 authors)
Current Oncology Reports
Open Access
Published: Mar 2023
9 citations
9 citations
16 days after retraction
Expression of concern—Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
The Editors of The Lancet Oncology
The Lancet Oncology
Published: Mar 2023
3 citations
3 citations
Same day as retraction
Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
Piotr Rutkowski, Anna M. Czarnecka
Annals of Translational Medicine
Open Access
Published: Jan 2023
1 citation
1 citation
56 days before retraction
Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
Yanhao Liu, Lan Yu, Yanjiao Liang et al. (11 authors)
Frontiers in Oncology
Open Access
Published: Jan 2023
6 citations
6 citations
64 days before retraction
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
Taku Fujimura, Yusuke Muto, Yoshihide Asano
International Journal of Molecular Sciences
Open Access
Published: Dec 2022
19 citations
19 citations
93 days before retraction
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
James S. Wilmott, Hussein A. Tawbi, Johnathan A. Engh et al. (18 authors)
Clinical Cancer Research
Open Access
Published: Dec 2022
14 citations
14 citations
97 days before retraction
Quoi de neuf en oncodermatologie ?
B. Baroudjian
Annales de Dermatologie et de Vénéréologie - FMC
Published: Dec 2022
103 days before retraction
Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
Michèle Welti, Florentia Dimitriou, Ralf Gutzmer et al. (4 authors)
Cancers
Open Access
Published: Nov 2022
14 citations
14 citations
126 days before retraction
Symptomatic melanoma CNS metastases in the TRICOTEL study – Authors' reply
Reinhard Dummer, Hussein A. Tawbi
The Lancet Oncology
Published: Nov 2022
3 citations
3 citations
133 days before retraction
Symptomatic melanoma CNS metastases in the TRICOTEL study
Andreas M. Schmitt, James Larkin
The Lancet Oncology
Published: Nov 2022
5 citations
5 citations
133 days before retraction
How I treat brain metastases of melanoma
Zeynep Eroglu, Turkan Ozturk Topcu, Ya-Yu Tsai et al. (4 authors)
ESMO Open
Open Access
Published: Oct 2022
7 citations
7 citations
145 days before retraction
Related Records
This article has multiple records in the database due to different notices:
Record #46041
Jul 14, 2023Quick Stats
Total Citations:
40
Years Since Retraction:
2.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025